SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Oncology Pharmacy Practice
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Dorr, R. T.
Right arrow Articles by Liddil, J. D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Dorr, R. T.
Right arrow Articles by Liddil, J. D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Stability of mitomycin C in different infusion fluids: Compatibility with heparin and glucocorticosteroids

Robert T. Dorr, PhD

College of Pharmacology, University of Arizona, Arizona Cancer Center, 1515 N. Campbell Avenue, Tucson, AZ, USA

James D. Liddil, MS

College of Pharmacology, University of Arizona, Arizona Cancer Center, 1515 N. Campbell Avenue, Tucson, AZ, USA

Introduction: Mitomycin C (Mutamycin) stability and compatibility was analyzed by reverse-phase high performance liquid chromatography (HPLC).

Methods: The drug was reconstituted in sterile water for injection USP, 0.9% sodium chloride for injection USP, 5% dextrose injection USP and lactated Ringer's injection USP. Samples were stored for vari ous times at —20°C, 4°C and 25°C in both glass and plastic (polyvinyl chloride) containers.

Results: Mitomycin C was shown to be stable (> 90% remaining for 5 to 7 days at room temperature in nondextrose containing infusion fluids. Greater stability was noted at drug concentrations ≥ 0.4 µg/mL and at reduced temperatures. In 5% dextrose solutions, stability was highly dependent upon pH: 3.4 hours at pH 4.7 and slightly over 24 hours at pH 5.5. Non-linear decomposition in dextrose was due to a slow increase in solution pH after adding mitomycin C. There were no stability differences for glass or plastic containers. Mitomycin was shown to be stable for prolonged periods when mixed with dexametha sone sodium phosphate (T 90% > 2 days), with hydro cortisone sodium succinate (T90% > 7 days) or with sodium heparin (T 90% > 2 days). Within these times, the concentrations of corticosteroids (measured by HPLC) and heparin (measured by bioassay) did not significantly decline.

Conclusions: Mitomycin C demonstrates pro longed stability in nonacidic infusion fluids. Long- term storage in dextrose-containing solutions should be avoided, but short-term admixture with heparin and corticosteroids is feasible.

Journal of Oncology Pharmacy Practice, Vol. 1, No. 3, 19-24 (1995)
DOI: 10.1177/107815529500100304


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement